Can you explain what you mean by subtyping and if/how it negates the usefulness of repurposing (if that’s what you meant to say). Wouldn’t subtyping complement a drug repurposing screen by allowing the scientist to test compounds against a subset of a disease?
And drug repurposing is also used for conditions with no known molecular basis like autism. You’re not suggesting its usefulness is limited in those cases right?
And drug repurposing is also used for conditions with no known molecular basis like autism. You’re not suggesting its usefulness is limited in those cases right?